[{"orgOrder":0,"company":"Formation Bio","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2024","type":"Series D Financing","leadProduct":"ASN008","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Formation Bio","amount2":0.37,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.37,"dosageForm":"Gel","sponsorNew":"Formation Bio \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Formation Bio \/ Sanofi"}]

Find Clinical Drug Pipeline Developments & Deals by Formation Bio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : The fund aims to advance the pipeline, which includes the company lead product ASN008, a sodium channel blocker. Currently, it is being evaluated for the treatment of atopic dermatitis.

                          Brand Name : ASN008

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 26, 2024

                          Lead Product(s) : ASN008

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Sanofi

                          Deal Size : $372.0 million

                          Deal Type : Series D Financing

                          blank